Figure INF-7:  Trends in HCV antibody prevalence estimated from national and sub-national samples of injecting drug users 1995 to 2004, in EU countries where data are available – Part (ii) Young injecting drug users (under age 25)

Figure INF-07 part ii

Notes:

Seroprevalence studies (SP) diagnostic testing (DT) unlinked anonymous testing (UAT).

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points.